Pharmaceutical composition for preventing or treating optic neuropathy comprising neural progenitor cells

A pharmaceutical composition using neural progenitor cells derived from human embryonic stem cells, administered via sub-Tenon injection, addresses the need for effective optic nerve regeneration by enhancing neuroprotection and axonal regeneration in optic neuropathy.

JP2024544268AInactive Publication Date: 2024-11-28COLLEGE OF MEDICINE POCHON CHA UNIV IND ACADEMIC COOP FOUND +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024535367
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-13
Filing Date
2022-11-18
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for irreversible optic nerve damage, such as optic neuropathy, lack effective clinical applications and there is a need for improved regenerative therapies.

Method used

A pharmaceutical composition containing neural progenitor cells, preferably SOX1-positive and PAX6-positive, derived from human embryonic stem cells, which are administered via sub-Tenon injection to promote neuroprotection and regeneration.

Benefits of technology

The neural progenitor cells exhibit superior neuroprotective and regenerative effects compared to mesenchymal stem cells, effectively promoting axonal regeneration and reducing inflammation, making them a promising treatment for optic neuropathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544268000001_ABST
    Figure 2024544268000001_ABST
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition for preventing or treating optic neuropathy, comprising neural progenitor cells as an active ingredient. Compared with mesenchymal stem cells such as placenta-derived stem cells (e.g., PSCs), neural progenitor cells not only exhibit significantly superior neuroprotective and regeneration-promoting effects, but also are non-invasive and can be administered by safe sub-Tenon injection. Therefore, the pharmaceutical composition of the present invention can be advantageously used as a cell therapy for treating optic neuropathy.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition for preventing or treating optic neuropathy, which comprises neural progenitor cells as an active ingredient. [Background technology]

[0002] As there is no effective treatment for irreversible damage to the optic nerve, many studies have attempted to improve the intrinsic regenerative capacity of retinal ganglion cells (RGCs). Macrophage activating factor and zymosan promote axonal regrowth after optic nerve injury. Alterations in the intrinsic regenerative capacity of RGCs can occur through phosphatase and tensin homolog (PTEN) deficiency. Induction of inflammation by injection of zymosan, combined with PTEN deficiency and promotion of intracellular cyclic adenosine monophosphate (cAMP) may help restore the optic nerve. However, it is difficult to use approved treatments in clinical trials.

[0003] For intractable eye diseases, embryonic stem cells (ESCs), corneal limbal stem cells, retinal pigment epithelial cells, and mesenchymal stem cells (MSCs) are used in cell therapy as part of regenerative medicine. MSCs release immunomodulatory factors, mediators, and chemokines to attract immune cells. MSCs also exert neuroprotective effects by secreting factors through paracrine action. Many studies using animal models of glaucoma have shown that intravitreal injection of MSCs increased the survival rate of RGCs. One study on an ischemia model showed that the number of RGCs and the expression of BDNF, ciliary neurotrophic factor (CNTF), and fibroblast growth factor (bFGF) increased after injection of MSCs. Also, several studies have confirmed the therapeutic effect of MSCs in ischemia models. Furthermore, in addition to bone marrow-derived MSCs, human umbilical cord blood, dental pulp, and placenta-derived MSCs have also shown therapeutic efficacy in terms of inducing regeneration and axonal growth in damaged optic nerves (Kwon, H. et al., Hypoxia-Preconditioned Placenta-Derived Mesenchymal Stem Cells Rescue Optic Nerve Axons via Differential Roles of Vascular Endothelial Growth Factor in an Optic Nerve Compression Animal Model. Mol. Neurobiol. 2020, 57, 3362-3375; Labrador-Velandia, S. et al., Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials. World J. Stem Cells 2016, 8, 376-383).

[0004] We have previously reported that regulating Hif-1α (hypoxia-inducible transcription factor 1α) and GAP43 (nerve growth-associated protein 43) in human placenta-derived MSCs (PSCs) promotes axon survival in an optic nerve crush (ONC) model (Chung, S. et al., Human umbilical cord blood mononuclear cells and chorionic plate-derived mesenchymal stem cells promote axon survival in a rat model of optic nerve crush injury. Int. J. Mol. Med. 2016, 37, 1170-1180). Regulation of the NF-κb pathway also plays a key role in regulating target proteins in PSCs. Another study has demonstrated the potential of using hypoxia-preconditioned PSCs (HPPCs) in cell therapy for optic nerve injury by investigating the effect of nerves regenerated from R28 cells and optic nerve injury animal models.

[0005] For example, numerous different molecules help regulate axon regeneration after optic nerve injury, including growth factors such as Wnt, CNTF, BDNF, and semaphorins; growth-inhibitory transcription factors such as KLF4 (Kruppel-like factor 4); and essential signaling mediators such as STAT3 (signal transducer and activator of transcription 3). The mechanism by which Wnt signaling promotes axon regeneration may involve the induction of these axon growth-promoting genes; Wnt signaling may also directly regulate growth cone remodeling by altering microtubule stability during axon growth. Summary of the Invention [Problem to be solved by the invention]

[0006] The present inventors have conducted various studies on the safety and clinical efficacy of neural progenitor cells (NPCs) derived from human pluripotent stem cells. As a result, the present inventors have found that NPCs exhibit significantly superior neuroprotective and regenerative effects in hypoxic R28 cell and optic nerve compression (ONC) models compared with mesenchymal stem cells such as human placenta-derived stem cells (e.g., PSCs), and therefore can be advantageously used as a cell therapy for the treatment of optic neuropathy.

[0007] Therefore, an object of the present invention is to provide a pharmaceutical composition for preventing or treating optic neuropathy, which comprises neural progenitor cells (NPCs) as an active ingredient. [Means for solving the problem]

[0008] According to the present invention, there is provided a pharmaceutical composition for preventing or treating optic neuropathy, which comprises neural progenitor cells as an active ingredient.

[0009] The neural progenitor cells may be neural progenitor cells derived from human embryonic stem cells, and preferably SOX1-positive and PAX6-positive neural progenitor cells derived from human embryonic stem cells.

[0010] The optic neuropathy may be one or more selected from the group consisting of ischemic optic neuropathy, optic neuritis, compressive optic neuropathy, infiltrative optic neuropathy, traumatic optic neuropathy, and mitochondrial optic neuropathy.

[0011] The pharmaceutical composition of the present invention may be in a dosage form for sub-Tenon injection. Effect of the Invention

[0012] The present invention has revealed that NPCs exhibit significantly superior neuroprotective and regenerative effects in hypoxic R28 cell and optic nerve compression (ONC) models compared with mesenchymal stem cells such as human placenta-derived stem cells (e.g., PSCs). In addition, the pharmaceutical composition of the present invention can be suitably administered by a non-invasive and safe administration route, i.e., sub-Tenon injection. Therefore, the pharmaceutical composition of the present invention can be advantageously used as a cell therapy for the treatment of optic neuropathy. [Brief description of the drawings]

[0013] [Figure 1] Characterization of human pluripotent stem cell-derived neural progenitor cells (NPCs). Figure 1A shows that CHA15 human ESCs were differentiated into NPCs by treatment with 5 μM PKCβ inhibitor and 1 μM DMH1 in DMEM / F12 medium supplemented with 10 μg / mL human insulin, 9 μg / mL transferrin, and 14 ng / mL selenite. Figure 1B shows that NPCs expanded at passage 1 were positive for two representative NPC markers, SOX1 (~90%) and PAX6 (~75.6%), but negative for the typical neural crest stem cell marker P75 (~0%). Figure 1C shows that further differentiation of NPCs into mature neurons produced both the early neuronal marker TUJ1 and the late neuronal marker MAP2.

[0014] [Diagram 2]This shows that human NPCs have the ability to restore damaged R28 cells. R28 cells were cultured with NPCs or hPSCs 3 hours before CoCl2 treatment. R28 cells were then treated with CoCl2 (300 μM). Figure 2A shows the results of the viability analysis performed after 24 hours. Data are presented as the percentage of viable cells (mean ± SEM) compared to the control group. Values ​​that were significantly different between groups are indicated with various symbols (p<0.05). Figure 2B shows the results of the measurement of the expression levels of apoptosis-related proteins. Figure 2C shows the Western blot analysis of the target protein expression levels. Quantitative values ​​of the expression levels of the target proteins are shown (lower panel) (*p<0.05 compared to control; #p<0.05 compared to CoCl2 treatment, ##p<0.01; †p<0.05 compared to PSCs).

[0015] [Diagram 3] We show that NPCs regulate axonal regeneration and inflammatory proteins in a rat model of retinal and optic nerve injury. Changes in target proteins were assessed by immunoblot analysis of rat retinal and optic nerve extracts. Samples were analyzed 1, 2, and 4 weeks after optic nerve compression injection. Expression levels were normalized to β-actin and OS values ​​were divided by OD. Figure 3A shows the quantitative expression levels of Hif-1α, Vegf, neurofilament, NeuN, Thy-1, and Gfap in retinal extracts. Figure 3B and Figure 3C show the quantitative expression levels of Bdnf, Iba1, Nlrp3, and Tnf-α in retinal extracts (B) and optic nerve tissue extracts (C). Results are presented as mean ± SEM of independent retinal and optic nerve analyses and expressed as fold change compared to controls (*p<0.05 compared to age-matched sham-operated (balanced salt solution (BSS)); #p<0.05 compared to PSC; ##p<0.01). OD, right eye; OS, left eye.

[0016] [Figure 4]Figures 4a and 4b show the RGC-promoting and axon regeneration-promoting effects of NPCs in the ONC model. Figure 4a, A and B show representative confocal microscopy fluorescence images of Brn-3a staining (A) and Tuj1 staining (B) (original magnification: 400x) after NPC or hPSC injection in the optic nerve compression animal model. Figure 4b, C and D show the results of fluorescence quantitative analysis of Gap43 (C) and Iba1 (D) performed at a distance of 500 μm from the ONC site of the optic nerve. Total GAP43-positive cells were measured using ZEN software. Two retinas and two optic nerves were used from each group. Results are expressed as mean ± standard error of the mean (SEM) (*p<0.05 compared to age-matched sham-treated (balanced salt solution); #p<0.05 compared to PSCs).

[0017] [Diagram 5] Figure 1 shows Wnt / β-catenin and Nf-κb during the recovery of injured R28 cells. R28 cells were co-cultured with NPCs or hPSCs and then exposed to CoCl2 (300 μM). After 24 h of incubation, Western blot analysis was performed. Results are expressed as mean ± standard error of the mean (SEM) (*p<0.05 compared to control; #p<0.05 compared to CoCl2 treatment). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] We previously reported that human placenta-derived mesenchymal stem cells (PSCs) have neuroprotective effects. To evaluate the potential benefits of NPCs, we compared NPCs with PSCs using R28 cells under hypoxic conditions and a rat model of optic nerve injury. NPCs or PSCs (2 × 10 each) were cultured in a 10-well plate at 4 °C for 1 h. 6100 pieces) were injected into the subtenon's space. Changes in target proteins in the retina and optic nerve were examined 1, 2, and 4 weeks after injection. Vascular endothelial growth factor (Vegf) was significantly induced in the NPC group after 2 weeks compared with age-matched sham and PSC groups. Neurofilaments were also induced in the retina in the NPC group after 4 weeks compared with the sham group. Furthermore, the expression of brain-derived neurotrophic factor (Bdnf) was higher in the retina of the NPC group after 2 weeks. The low expression of ionized calcium-binding adaptor molecule 1 (Iba1) in the retina was restored 2 weeks after NPC injection and 4 weeks after PSC injection. The expression of pyrin domain-containing protein 3 (Nlrp3), a member of the inflammatory protein NLR family, in the optic nerve was significantly decreased in the NPC group after 1 week, and the expression of tumor necrosis factor alpha (Tnf-α) in the optic nerve was decreased after 2 weeks. Regarding retinal ganglion cells, the expression of Brn3a and Tuj1 in the retina was enhanced in the NPC group after 4 weeks compared with sham-treated controls. NPC injection increased the expression of Gap43 from 2 weeks and decreased the expression of Iba1 in the optic nerve during the recovery period. Furthermore, R28 cells exposed to hypoxic conditions showed increased cell viability when co-cultured with NPCs compared with PSCs. Both Wnt / β-catenin signaling and increased Nf-κb can contribute to the rescue of damaged retinal ganglion cells through the upregulation of neuroprotective factors, microglial involvement and anti-inflammatory regulation by NPCs. Thus, this study demonstrated that NPCs are useful for cell therapy of various optic neuropathies.

[0019] In light of this, the present invention provides a pharmaceutical composition for preventing or treating optic neuropathy, which comprises neural progenitor cells as an active ingredient.

[0020] Neural progenitor cells (NPCs) are the precursor cells of the CNS that give rise to many, if not all, glial and neuronal cells. NPCs are present in the developing embryonic CNS, but are also found in the neonatal brain and the mature adult brain. NPCs can be generated in vitro by differentiating embryonic stem cells or induced pluripotent stem cells (iPSCs). Preferably, the neural progenitor cells can be neural progenitor cells derived from human embryonic stem cells, more preferably SOX1-positive and PAX6-positive neural progenitor cells derived from human embryonic stem cells.

[0021] Optic neuropathy refers to damage to the optic nerve caused by various causes. Optic neuropathy is characterized by the damage and death of nerve cells or neurons. Optic neuropathy, also known as optic nerve atrophy, is the end result of a disease in which nerve cells between retinal ganglion cells and the lateral geniculate body are damaged. Therefore, in the pharmaceutical composition of the present invention, optic neuropathy includes various forms of optic neuropathy, and may be one or more selected from the group consisting of ischemic optic neuropathy; optic neuritis; compressive optic neuropathy; infiltrative optic neuropathy; traumatic optic neuropathy; and mitochondrial optic neuropathy, such as nutritional optic neuropathy, toxic optic neuropathy, and hereditary optic neuropathy.

[0022] The pharmaceutical composition of the present invention may contain a pharma- ceutically acceptable carrier, such as an emulsifier, a suspending agent, a buffer, an isotonicity agent, etc. The pharmaceutical composition of the present invention may be formulated into a parenteral dosage form. In particular, the pharmaceutical composition of the present invention can be suitably administered by a non-invasive and safe administration route, i.e., sub-Tenon injection. Thus, the pharmaceutical composition of the present invention may have a dosage form for sub-Tenon injection. The dosage form for sub-Tenon injection can usually be prepared by preparing a sterile solution of the active ingredient; it may contain a buffer that can appropriately adjust the pH of the solution, and may contain an isotonicity agent so that the formulation is given isotonicity.

[0023] In addition, the pharmaceutical composition according to the present invention was administered to a patient with optic neuropathy at a dose of about 1×10 7 ~1×10 8 pcs, preferably about 5 x 10 7This daily dose may be administered once or multiple times and can vary depending on the age and condition of the patient.

[0024] The present invention will be described in more detail below with reference to examples and test examples. However, these examples and test examples are intended to illustrate the present invention and are not intended to limit the present invention. EXAMPLES

[0025] 1. Materials and Methods (1) In vitro testing (1-1) Production of neural progenitor cells (NPCs) derived from human pluripotent stem cells Human pluripotent stem cell culture TeSR was cultured on Matrigel-coated culture dishes (BD Biosciences, San Jose, CA, USA). TM -E8 TM H9 human ESCs (WiCell Research Institute, Madison, WI, USA) were maintained in medium (STEMCELL Technologies, Vancouver, BC, Canada). For passaging, 0.5 mM EDTA (Thermo Fisher Scientific, Waltham, MA, USA) was added and the ESCs were incubated in a CO2 incubator at 37 °C for 3 min, then the ESCs were transferred to TeSR containing 10 μM Y-27632 (Sigma-Aldrich, St. Louis, MO, USA). TM -E8 TM The cells were split at a ratio of 1:20 onto a Matrigel-coated dish containing medium. Two days after passage, the cells were cultured in TeSR medium without Y-27632. TM -E8 TM The medium was changed daily with culture medium. Experiments using hESCs were approved by the Institutional Review Board (IRB) of CHA University (IRB No. 1044308-201603-LR-004-09).

[0026] Embryoid body (EB) formation and NPC induction Human ESCs were detached using 2 mg / mL type IV collagenase (Worthington Biochemical Corporation, Lakewood, NJ, USA) at 37°C for 30 min. EBs were formed from the detached ESCs and cultured in suspension for 4 days in DMEM / F12 medium (Thermo Fisher Scientific) containing 10 μg / mL human insulin, 9 μg / mL transferrin, 14 ng / mL selenite, 5 μM PKCβ inhibitor, and 1 μM DMH1 (all from Sigma-Aldrich). The culture medium was changed daily. On the fourth day of culture, EBs were transferred to Matrigel-coated dishes containing NPC specification medium containing 1% N2 supplement (Thermo Fisher Scientific), 20 ng / mL bFGF (CHAbiotech, Pangyo, Korea), and 25 μg / mL human insulin. The medium was changed daily for 5 days to generate neural rosettes.

[0027] Flow cytometry analysis Cells were dissociated into single cells by treatment with Accutase (Thermo Fisher Scientific) for 5 min at 37°C and fixed in 4% paraformaldehyde / phosphate-buffered saline (PBS) for 15 min at room temperature. Fixed cells were treated with 0.2% TritonX-100 (Sigma-Aldrich) / PBS for 15 min at room temperature and incubated in blocking solution (1% BSA / PBS) for 30 min at room temperature. Cells were stained overnight at 4°C with anti-SOX1-PE or anti-PAX6-APC antibodies (both purchased from Miltenyi Biotec GmbH, Bergisch Gangladbach, Germany). Anti-p75-PE antibody (Miltenyi Biotec GmbH) targets the cell surface antigen p75 and was not permeabilized. Isotype-matched IgG was used as a control. Cells were washed once with 1% BSA / PBS and analyzed using a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA).

[0028] immunocytochemistry Cells were fixed in 4% paraformaldehyde / PBS and permeabilized with 0.2% TritonX-100 for 15 min at room temperature. Cells were blocked with 5% BSA / PBS for 1 h at room temperature and treated with primary antibodies overnight at 4°C. Primary antibodies used were antibodies targeting TuJ1 (Covance, Burlington, NC, USA) or MAP2 (Millipore, Burlington, MA, USA), and fluorescently labeled secondary antibodies used were Alexa Fluor 488 and Alexa Fluor 594, respectively (both purchased from Thermo Fisher Scientific). After treatment with secondary antibodies, samples were treated with 4',6-diamidino-2-phenylindole (Sigma-Aldrich) for 10 min. Images were taken using a ZEISS fluorescence microscope (ZEISS, Oberkochen, Germany).

[0029] (1-2) Production of human placenta-derived mesenchymal stem cells (PSCs) Human placenta stem cells were collected from CHA General Hospital, Seoul, Korea. Sample collection and use for research purposes were approved by the hospital's IRB. PSC production and culture procedures were performed according to a previous report (Park, M. et al., Human placenta mesenchymal stem cells promote axon survival following optic nerve compression through activation of NF-kappaB pathway. J. Tissue Eng. Regen. Med. 2018, 12, e1441-e1449).

[0030] (1-3) Cell culture and treatment R28 retinal progenitor cells were cultured in Dulbecco's modified Eagle's minimal medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 1x minimum essential medium (MEM) with non-essential amino acids (Thermo Fisher Scientific), 100 μg / mL gentamicin (Sigma-Aldrich), and 1% penicillin-streptomycin (Thermo Fisher Scientific). Hypoxic conditions were induced by exposing R28 cells to cobalt chloride (CoCl2) (Sigma-Aldrich). R28 cells (2 × 10 5 NPCs or hPSCs were co-cultured with R28 cells 3 h before treatment with CoCl2 (300 μM). R28 cells were then treated with CoCl2 (300 μM) and samples were prepared for experiments 24 h later.

[0031] (1-4) Cell viability analysis Hypoxia-treated R28 cells were cultured to culture NPCs or PSCs (2 × 10 5 After co-culture with 100 μg / ml of 10 ...

[0032] (1-5) Immunoblot analysis Optic nerve tissue was used to analyze regenerative and inflammatory markers. Lysates were prepared from optic nerve tissue using PRO-PREP solution (iNtRON Biotechnology, Gyeonggido, Korea). Total proteins were loaded in equal amounts, separated by SDS-PAGE, and transferred to membranes. Anti-Thy-1 antibody (SC-53116), anti-β-actin antibody (SC-47778) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Vegf antibody (GTX102643), anti-Tnf-α antibody (GTX10520), anti-β-catenin antibody (GTX101435), anti-Wnt3a antibody (GTX128101) (GeneTex, Ir. vine, CA, USA), anti-GFAP antibody (#3670), anti-neurofilament antibody (#2837), anti-t caspase 3 antibody (#9662), anti-Bcl2 antibody (#2764), anti-Nf-κb antibody (#8242) (Cell Signaling The membranes were incubated with anti-Hif-1α (PA1-16601), anti-Bdnf (PA5-85730), anti-Iba1 (PA5-27436) (Thermo Fisher Scientific), anti-Nlrp3 (NBP2-12446) (Novus Biologicals, Centennial, CO, USA), or anti-NeuN (MABB377) (Millipore). All antibodies were used at a dilution of 1:1000, except for anti-Thy-1 (1:200 dilution). After washing steps, the membranes were incubated overnight at 4°C with horseradish peroxidase-conjugated anti-rabbit or mouse secondary antibodies diluted 1:10000. Immunoreactive bands were visualized with enhanced chemiluminescence solution (Bio-Rad Laboratories, Hercules, CA, USA) and analyzed by ImageQuant. TM Detection was performed using a LAS 4000 (GE Healthcare, Chicago, IL, USA).

[0033] (2) In vivo testing (2-1) Animals and test groups Six-week-old male Sprague-Dawley (SD) rats (Orient Bio, Gyeonggido, Korea) were housed in a standard animal facility with food and water provided at a constant temperature of 21 °C. The in vivo study protocol was approved by the Animal Care and Use Committee of Bundang CHA Medical Center (IACUC200138). Rats were divided into the following groups: sham group (injected with BSS (balanced salt solution) after optic nerve compression); NPC group (injected with 2 × 10 6 cells / 0.06 mL injected); PSC group (2 × 10 6 (0.06 mL / injection) After 1, 2, and 4 weeks, the rats were euthanized.

[0034] (2-2) Optic nerve compression model and sub-Tenon cell injection Rats were anesthetized with Zoletil and Rompun. The animal model was prepared as described in a previous study (Chung, S. et al., Human umbilical cord blood mononuclear cells and chorionic plate-derived mesenchymal stem cells promote axon survival in a rat model of optic nerve crush injury. Int. J. Mol. Med. 2016, 37, 1170-1180). After topical application of 0.5% proparacaine hydrochloride, a vermis incision and conjunctival incision were made. The tissue surrounding the optic nerve was incised. An ultrafine reverse action forceps was used to compress the optic nerve 2 mm posterior to the globe for 5 seconds. Optic nerve compression (ONC) was performed in the left eye (OS). The canthal incision was then sutured. After the canthal area was completely sutured, NPCs or PSCs were injected sub-Tenon into the nasal side of the rat's eye.

[0035] (2-3) Evaluation of axon regeneration factors in the optic nerve of the ONC model For in vivo measurement of axon regeneration, vertical sections of the optic nerve stained with GAP43 were photographed. First, the optic nerve was fixed in 4% paraformaldehyde and embedded in paraffin. The optic nerve was vertically sectioned at a thickness of 20 μm and mounted on glass slides. Regenerating fibers were stained using anti-GAP43 antibody (1:200, ab7810; Abcam, Cambridge, UK) or anti-Iba1 antibody (1:200, PA5-27436, Thermo Fisher Scientific). The measurement site was a rectangular area of ​​150 μm width × 700 μm height on the ONC region side, and the average value was calculated. The total number of GAP43-positive cells or the total number of Iba1-positive cells was measured using ZEN software (Carl Zeiss, Jena, Germany).

[0036] (2-4) Flat-mounted retinas and RGC survival analysis Eyes were enucleated from three rats in each treatment group, and retinas were dissected to prepare flat whole-mount preparations. First, the cornea was excised by making a circular incision along the ora serrata with small scissors, and then the lens was removed using forceps. Then, the retina was separated from the optic cup by placing forceps between the retina and the optic cup. After obtaining the whole retina, the retina was cut into four equal parts by dissecting from the retina toward the optic nerve with scissors as described in a previous study (Kwon, H. et al., Hypoxia-Preconditioned Placenta-Derived Mesenchymal Stem Cells Rescue Optic Nerve Axons via Differential Roles of Vascular Endothelial Growth Factor in an Optic Nerve Compression Animal Model. Mol. Neurobiol. 2020, 57, 3362-3375). Retinas were fixed in 4% paraformaldehyde and mounted with glass coverslips at room temperature for at least 1 hour. Retinal preparations were washed with PBS and then incubated in PBS containing 1% TritonX-100 for 30 min at room temperature. Retinas were blocked with 20% fetal bovine serum for 1 h and incubated overnight at 4 °C with anti-Tuj1 (ab18207; Abcam) or anti-Brn-3a (MAB1585; Millipore) antibodies diluted 1:10. The next day, retinas were washed with PBS-T and incubated for 2 h with Alexa Fluor 633 goat anti-rabbit IgG-fluorescein isothiocyanate antibody diluted 1:200 in PBS-T. Retinas were washed again and then mounted with a coverslip. Fluorescence was quantified using images taken with a confocal microscope (LSM 880; Carl Zeiss, Jena, Germany). Fluorescence was calculated in two areas for each retina and statistical analysis was performed by comparing the mean values.

[0037] (3) Statistical analysis Data analysis was performed using GraphPad Prism9 (GraphPad, La Jolla, CA, USA). Statistical significance was determined using t-tests or nonparametric statistical tests, followed by Mann-Whitney U-tests at a significance level of 5%.

[0038] 2.Results (1) Characterization of neural progenitor cells (NPCs) derived from human pluripotent stem cells CHA15 human ESCs were differentiated into NPCs by treatment with 5 μM PKCβ inhibitor and 1 μM DMH1 in DMEM / F12 medium supplemented with 10 μg / mL human insulin, 9 μg / mL transferrin, and 14 ng / mL selenite (Figure 1A). NPCs expanded at passage 1 were positive for two representative NPC markers, SOX1 (~90%) and PAX6 (~75.6%), but negative for the typical neural crest stem cell marker P75 (~0%) (Figure 1B). Further differentiation of NPCs into mature neurons produced both the early neuronal marker TUJ1 and the late neuronal marker MAP2 (Figure 1C).

[0039] (2) NPC reduces cell apoptosis and regulates target proteins To evaluate the restorative function of NPCs, we performed cell viability tests. When damaged R28 cells were co-cultured with NPCs or PSCs, the viability of the damaged R28 cells was restored by 48% and 7%, respectively, compared to that under hypoxic conditions (Figure 2A). NPCs also regulated the activity of cleaved caspase 3 and the expression of Bcl-2 protein in apoptosis (Figure 2B). We also found that Hif-1α caused less hypoxic damage when co-cultured with PSCs. In contrast to Hif-1α, the expression levels of neurofilament (Nf), Gap43, NeuN, and Gfap, which were decreased under hypoxic conditions, were significantly restored by co-culture with NPCs (Figure 2C).

[0040] (3) Changes in the expression of neural markers in the retina after injection of NPCs or PSCs in an animal model of optic nerve compression The expression regulation of Hif-1α, Vegf, neurofilament, NeuN, Thy-1, and Gfap proteins in rat retinas was analyzed by Western blot at 1, 2, and 4 weeks after optic nerve compression. At 1 week, coculture with NPCs or PSCs significantly increased the expression of Thy-1 compared with age-matched sham-treated groups. Coculture with NPCs also significantly induced Vegf in the retina compared with sham-treated and PSC groups. Furthermore, at 4 weeks, coculture with NPCs increased the induction of neurofilament compared with sham-treated groups (Figure 3A).

[0041] (4) Comparison of target protein expression levels between retina and optic nerve tissue in the optic nerve compression model Using the ONC model, we compared the expression levels of target proteins in the retina and optic nerve. At 2 weeks, the expression level of BDNF in the retina was higher in the NPC group, whereas the expression level in the optic nerve was higher in both the NPC and PSC groups. The expression of Iba1, which was decreased in the retina, was restored 2 weeks after NPC injection and 4 weeks after PSC injection (Figure 3B). In the optic nerve of the NPC group, the expression level of the inflammatory protein Nlrp3 was significantly decreased at 1 week, and the expression level of TNF-α was significantly decreased at 2 weeks (Figure 3C).

[0042] (5) Protective effects of NPCs and PSCs on retinal RGCs in an animal model of optic nerve compression We assessed RGC survival by counting the number of RGCs stained for Brn-3a or Tuj1 in rat retinas. After optic nerve compression (ONC), only NPCs were found to have significantly increased retinal Brn-3a and Tuj1 expression at 4 weeks compared with age-matched sham-treated groups (Figure 4A, A and B).

[0043] (6) Effects of NPCs and PSCs on optic nerve axonal damage in animal models of optic nerve injury The protective effect of NPC injection on the optic nerve was evaluated by counting GAP43- and Iba1-positive cells in the optic nerve of the ONC model. As shown in Fig. 4B, C, the expression of GAP43 in the NPC- and PSC-treated groups was significantly increased at week 2 compared to the ONC group, but only NPC injection showed significant recovery at week 4. NPC injection also reduced the expression of Iba1 in the optic nerve over 4 weeks, indicating that NPCs can promote microglial involvement in the retina during the recovery period (Fig. 4B, D).

[0044] (7) Wnt / β-catenin signaling is involved in the recovery of retinal ganglion cells by NPCs Previous studies have reported that Wnt / β-catenin signaling and NF-κb protein are related to neuroprotection by MSCs (Dvoriantchikova, G. et al., Virally delivered, constitutively active NFkappaB improves survival of injured retinal ganglion cells. Eur. J. Neurosci. 2016, 44, 2935-2943; Liu, X. et al., Interaction of NF-kappaB and Wnt / beta-catenin Signaling Pathways in Alzheimer's Disease and Potential Active Drug Treatments. Neurochem. Res. 2021, 46, 711-731). We investigated whether Wnt / β-catenin signaling may be involved in the mechanism of recovery by NPCs of injured R28 cells. We found that Wnt / β-catenin signaling mediated the recovery process induced by NPCs. Co-culture of R28 cells with NPCs significantly rescued the CoCl2-induced decrease in Wnt3a compared with the control group. In addition, the expression level of NF-κb was maintained at a similar level to normal in the NPC group, whereas the expression level of NF-κb in the PSC group was lower than that in the normal (and NPC) groups (Figure 5).

[0045] 3. Discussion MSCs can be easily harvested from body fat, bone marrow, placenta and umbilical cord. MSCs are also immune privileged because they low-express HLA class I antigens and do not or very low-express CD80, CD86, CD40 and HLA class II antigens. In addition, MSCs are useful for cell therapy due to other unique characteristics such as ease of isolation, rapid proliferation after a short period of rest, and avoidance of ethical issues. Meanwhile, NPCs are derived from various conditions and chemical inductions in various experiments, unlike MSCs such as PSCs (Kim, HM et al., Fine-tuning of dual-SMAD inhibition to differentiate human pluripotent stem cells into neural crest stem cells. Cell Prolif. 2021, 54, e13103).

[0046] The mechanisms by which MSCs directly regulate neuroprotection remain unclear. PSCs are thought to promote axon survival in rats by regulating Hif-1α and GAP43 (Chung, S. et al., Human umbilical cord blood mononuclear cells and chorionic plate-derived mesenchymal stem cells promote axon survival in a rat model of optic nerve crush injury. Int. J. Mol. Med. 2016, 37, 1170-1180) and mediating the NF-κb pathway (Dvoriantchikova, G. et al., Virally delivered, constitutively active NFkappaB improves survival of injured retinal ganglion cells. Eur. J. Neurosci. 2016, 44, 2935-2943); Liu, X. et al., Interaction of NF-kappaB and Wnt / beta-catenin Signaling Pathways in Alzheimer's Disease and Potential Active Drug Treatments. Neurochem. Res. 2021, 46, These results suggest that MSC therapy may be useful for the treatment of optic nerve damage, but the pathways important for optic nerve recovery remain unknown.

[0047] In this study, we investigated various mediated proteins and pathways of NPCs associated with the recovery process of RGC precursor cells. The expression of nerve cell regeneration markers Gap43, Thy-1, and neurofilament was induced by NPCs. We also confirmed the function of NPCs in vivo and in vitro. The neuroprotective and regeneration-promoting effects of NPCs were significantly superior to those of PSCs. To compare the therapeutic roles of PSCs and NPCs, we performed a BDNF-mediated functional analysis. The expression of BDNF in the retina was significantly higher in the NPC group, whereas the expression of BDNF in the optic nerve was higher in both the NPC and PSC groups. These results indicated that NPCs are effective in the recovery of optic ganglion cells, which are the origin of optic nerve axons.

[0048] In this study, PSCs and NPCs were associated with the expression of Iba1 protein. During the recovery period, the expression of Iba1 in retinal microglia induced by NPCs was significantly higher than that by PSCs. After optic nerve injury, activated microglia were observed to migrate from the optic nerve to the retina and participate in the cellular response for axonal survival and removal in the injured retina (Heuss, ND et al., Optic nerve as a source of activated retinal microglia post-injury. Acta Neuropathol. Commun. 2018, 6, 66). The expression of Iba-1, a microglial biomarker, is associated with microglial polarization. In the process of neuroprotection, the conversion of microglia from M1 to M2 phenotype was induced (Cui, W. et al., Inhibition of TLR4 Induces M2 Microglial Polarization and Provides Neuroprotection via the NLRP3 Inflammasome in Alzheimer's Disease. Front. Neurosci. 2020, 14, 444). In addition, the use of electroacupuncture to treat neurodegenerative diseases such as Alzheimer's disease enhanced the activation of M2 markers arginase 1 (Arg1) and Iba1 positive cells in the hippocampus (Xie, L. et al., Electroacupuncture Improves M2 Microglia Polarization and Glia Anti-inflammation of Hippocampus in Alzheimer's Disease. Front. Neurosci. 2021, 15, 689-629). Induction of Iba1 expression in the retina may contribute to the expression of M2 biomarkers in the process of neuroprotection after optic nerve injury. Therefore, NPCs may be more efficient for neurorehabilitation after hypoxic injury.Notably, NPCs may rescue injured RGCs better than PSCs through cell-cell interactions, considering that the restorative effect of NPCs is more closely related to microglia-mediated neuroprotection.

[0049] The type of ocular disease determines the route of administration of stem cells. For retinal diseases such as retinitis pigmentosa, Stargardt's disease, and age-related macular degeneration, intravitreal injection is usually used. We injected PSCs or NPCs via the sub-Tenon route, which is less invasive and safer for repeated injections compared to other routes such as intravenous and intravitreal administration. Sub-Tenon injection of NPCs maintained a longer lasting effect compared to injection of the same number of PSCs.

[0050] In conclusion, NPCs had beneficial effects on hypoxic-injured R28 cells and ONC animal models. NPCs could rescue damaged RGCs through upregulation of neuroprotective factors mediated by Wnt / β-catenin signaling and Nf-κb, microglial involvement and anti-inflammatory regulation. Thus, NPCs could be used as a useful cell therapy for various optic neuropathies.

Claims

1. A pharmaceutical composition for preventing or treating optic neuropathy, comprising neural progenitor cells as an active ingredient.

2. The pharmaceutical composition according to claim 1 , wherein the neural progenitor cells are neural progenitor cells derived from human embryonic stem cells.

3. The pharmaceutical composition according to claim 1 , wherein the neural progenitor cells are SOX1-positive and PAX6-positive neural progenitor cells derived from human embryonic stem cells.

4. The pharmaceutical composition according to claim 1, wherein the optic neuropathy is one or more selected from the group consisting of ischemic optic neuropathy, optic neuritis, compressive optic neuropathy, infiltrative optic neuropathy, traumatic optic neuropathy, and mitochondrial optic neuropathy.

5. The pharmaceutical composition according to any one of claims 1 to 4, which has a dosage form for sub-Tenon injection.

Citation Information

Patent Citations

  • Use of anecortave acetate as an adjunct during bleb surgery

    JP2009521511A

  • Double-stranded RNA compounds for CASP2 and their use

    JP2015507478A

  • Test Device for Non-explosive Underwater Shock Test of Ship

    KR1020220123842A

  • Human Persistent Fetal Vasculature Neural Progenitors for Transplantation in the Inner Retina

    US20150125432A1

  • Therapeutic / preventive agent for intraocular disease containing statin compound

    WO2008044339A1